-
Mashup Score: 3Untangling Tau | Biogen - 6 month(s) ago
The expression of tau in the brain is linked to the symptomatology of Alzheimer’s, and while the precise toxic form of the protein is not yet understood, Dominic Walsh, Ph.D., head of Biogen’s Neurodegenerative Diseases Unit, believes that it is still possible to develop effective therapies for the disease.
Source: www.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Amyotrophic lateral sclerosis | Biogen - 1 year(s) ago
For over a decade, Biogen has been committed to advancing ALS research in order to provide a deeper understanding of all forms of this devastating disease.
Source: www.biogen.comCategories: Latest Headlines, Rare DiseaseTweet-
.@biogen Do you perhaps have incident annual cases here and not prevalent cases? Something seems very off with that number to me. https://t.co/chESfDoIIV https://t.co/UJEUYOdZuM
-
-
Mashup Score: 0Update on Tofersen Clinical Program - 3 year(s) ago
Update on Tofersen Early Access Program Part 1 Part 1 of Biogen’s Early Access Program (EAP) for the most rapidly progressing SOD1-ALS patients is now open. Beginning June 25, 2021, physicians may submit requests on behalf of patients who meet the inclusion/exclusion criteria by emailing MedicineAccess@clinigengroup.com. Biogen will be ready to ship tofersen to eligible sites to be available…
Source: www.biogen.comCategories: Latest Headlines, Rare DiseaseTweet-
News from @biogen https://t.co/CGl0ofzPt2 HT @KickALS
-
-
Mashup Score: 2Update on Tofersen Clinical Program - 3 year(s) ago
Update on Tofersen Clinical Program: Dear members of the ALS community, Below is an update on Biogen’s tofersen clinical program. About Biogen’s Investigational Therapy, Tofersen, for SOD1-ALS Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in…
Source: www.biogen.comCategories: Latest Headlines, Rare DiseaseTweet-
RT @takmad: In case my ALS colleagues haven’t seen this yet. @alsadvocacy (help spread the news) https://t.co/piTXjXOYPc
-
-
Mashup Score: 3Update on Tofersen Clinical Program - 3 year(s) ago
Update on Tofersen Clinical Program: Dear members of the ALS community, Below is an update on Biogen’s tofersen clinical program. About Biogen’s Investigational Therapy, Tofersen, for SOD1-ALS Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). A mutation in the SOD1 gene is believed to be a genetic driver of disease in…
Source: www.biogen.comCategories: Latest Headlines, Rare DiseaseTweet-
Logjam breaking... https://t.co/fAu8Ke3tOw
-
-
Mashup Score: 1A message from Alfred Sandrock - 3 year(s) ago
A message from Alfred Sandrock, EVP Research & Development about ALS investigational therapy I want to extend my deepest gratitude to the many of you who have expressed to me and others at Biogen your concern for people living with ALS. Their experiences have touched all of us at Biogen and reinforced our commitment to finding effective and safe therapies to treat this…
Source: www.biogen.comCategories: Latest Headlines, Rare DiseaseTweet-
A message from Alfred Sandrock https://t.co/XvodmJha1j
-
The progression and distribution of tau in the brain is tied to symptoms in #AlzheimersDisease. Using what we know and recognizing what we don’t know about the protein is key to developing potential treatments. Read more: https://t.co/7W7WC3YHl8